PA
RNAC icon

Parallel Advisors’s Cartesian Therapeutics RNAC Stock Holding History

Parallel Advisors’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18 Hold
103
– – ﹤0.01% 3817
2025
Q4 		$22 Hold
103
– – ﹤0.01% 3595
2025
Q3 		$31 Hold
103
– – ﹤0.01% 3520
2025
Q2 		$31 Buy
103
+100
+3,333% +$1.06K ﹤0.01% 3504
2025
Q1 		$40 Hold
3
– – ﹤0.01% 3471
2024
Q4 		$54 Hold
3
– – ﹤0.01% 3476
2024
Q3 		$48 Hold
3
– – ﹤0.01% 3362
2024
Q2 		$81 Hold
3
– – ﹤0.01% 3256
2024
Q1 		$65 Sell
3
-4
-57% -$85 ﹤0.01% 3221
2023
Q4 		$69 Buy
7
+4
+133% +$119 ﹤0.01% 3243
2023
Q3 		$106 Hold
3
– – ﹤0.01% 3275
2023
Q2 		$112 Hold
3
– – ﹤0.01% 3279
2023
Q1 		$139 Hold
3
– – ﹤0.01% 3308
2022
Q4 		$113 Hold
3
– – ﹤0.01% 3250
2022
Q3 		$0 Hold
3
– – ﹤0.01% 3440
2022
Q2 		$0 Hold
3
– – ﹤0.01% 3299
2022
Q1 		$0 Hold
3
– – ﹤0.01% 3228
2021
Q4 		$0 Hold
3
– – ﹤0.01% 3262
2021
Q3 		$0 Hold
3
– – ﹤0.01% 3243
2021
Q2 		$0 Hold
3
– – ﹤0.01% 3043
2021
Q1 		$0 Sell
3
-4
-57% -$497 ﹤0.01% 2883
2020
Q4 		$1K Buy
+7
New +$607 ﹤0.01% 2474

Other funds holding RNAC

Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Parallel Advisors's RNAC Position: Q1 2026 in Review

Parallel Advisors held its Cartesian Therapeutics (RNAC) position steady in Q1 2026 at 103 shares worth $18. The position accounts for ﹤0.01% of the portfolio, ranked #3817.

Parallel Advisors first reported a position in RNAC in Q4 2020 and has held it in 22 quarters since. The position peaked at $1K in Q4 2020. 83 funds tracked by Wall St. Rank hold RNAC as of Q1 2026.

  • Parallel Advisors held 103 shares of Cartesian Therapeutics worth $18 as of Q1 2026.
  • Parallel Advisors left its Cartesian Therapeutics share count unchanged in Q1 2026.
  • Cartesian Therapeutics made up ﹤0.01% of Parallel Advisors's portfolio in Q1 2026, its #3817 holding.
  • Parallel Advisors first reported a position in Cartesian Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • Parallel Advisors's Cartesian Therapeutics position peaked at $1K in Q4 2020.
  • 83 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2026.

Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.